Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Independence from the rat race for Recent college grads: Systems and Tips - 2Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- 3Find the Insider facts of Compelling Systems administration: Building Associations for Progress
- 4Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- 5AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Green Inflections: A Manual for Inside Plants
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- The 10 Most Famous Works of art Ever
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Manual for 6 famous sorts of cheddar
